Spangfort Michael D, Larsen Jørgen Nedergaard
ALK-Abelló, Bøge Allé 6-8, DK - 2970 Hørsholm, Denmark.
Immunol Allergy Clin North Am. 2006 May;26(2):191-206, v-vi. doi: 10.1016/j.iac.2006.02.012.
In the 1970s and 1980s, scientific methods were introduced in the standardization of allergen vaccines and, in combination with improved documentation of the clinical benefits obtained using standardized vaccines, specific allergy treatment as a scientifically based, reproducible, and safe treatment for allergic disease was established. This article describes important issues in the control of source materials and vaccine preparation as part of the European standardization of allergen vaccines, and also includes a discussion of vaccines that are based on recombinant allergens, which may appear on the market in the near future.
在20世纪70年代和80年代，科学方法被引入变应原疫苗的标准化过程中。结合使用标准化疫苗所获得的临床益处的更完善记录，特异性变态反应治疗作为一种基于科学、可重复且安全的变态反应性疾病治疗方法得以确立。本文描述了作为变应原疫苗欧洲标准化一部分的原材料控制和疫苗制备中的重要问题，还包括对基于重组变应原的疫苗的讨论，这类疫苗可能在不久的将来投放市场。
